Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) EBIT (2016 - 2025)

Ironwood Pharmaceuticals (IRWD) has disclosed EBIT for 16 consecutive years, with -$77.0 million as the latest value for Q4 2025.

  • Quarterly EBIT fell 344.49% to -$77.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14.7 million through Dec 2025, down 84.21% year-over-year, with the annual reading at $14.7 million for FY2025, 84.21% down from the prior year.
  • EBIT hit -$77.0 million in Q4 2025 for Ironwood Pharmaceuticals, down from $75.5 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $75.5 million in Q3 2025 to a low of -$1.1 billion in Q2 2023.
  • Historically, EBIT has averaged -$37.1 million across 5 years, with a median of $38.8 million in 2023.
  • Biggest five-year swings in EBIT: surged 243.22% in 2021 and later tumbled 2046.17% in 2023.
  • Year by year, EBIT stood at -$133.5 million in 2021, then grew by 3.42% to -$129.0 million in 2022, then soared by 129.15% to $37.6 million in 2023, then dropped by 16.22% to $31.5 million in 2024, then plummeted by 344.49% to -$77.0 million in 2025.
  • Business Quant data shows EBIT for IRWD at -$77.0 million in Q4 2025, $75.5 million in Q3 2025, and $45.3 million in Q2 2025.